< 返回主頁

COVID-19 Is a Coronary Artery Disease Risk Equivalent and Exhibits a Genetic Interaction With ABO Blood Type

by | 10月 9, 2024 | 科學抗疫, 病毒、病理生理學

對不起,此内容只適用於English

By James R. Hilser et al.

Source AHAjournals

People with whatever COVID-19 infection were twice as likely to have a major cardiac event, such as heart attack, stroke or even death, for up to three years after diagnosis.

The risk was significantly higher for patients hospitalized for COVID-19 and more of a determinant than a previous history of heart disease.

Individuals with a blood type other than an O (such as A, B or AB) were twice as likely to experience an adverse cardiovascular event after COVID-19 than those with an O-blood type.

Considering that over a billion people already had COVID-19 and 60% of population are not O-blood type.

So, what is your blood type ?

Abstract
BACKGROUND:
COVID-19 is associated with acute risk of major adverse cardiac events (MACE), including myocardial infarction, stroke, and mortality (all-cause). However, the duration and underlying determinants of heightened risk of cardiovascular disease and MACE post–COVID-19 are not known.
METHODS:
Data from the UK Biobank was used to identify COVID-19 cases (n=10 005) who were positive for polymerase chain reaction (PCR+)-based tests for SARS-CoV-2 infection (n=8062) or received hospital-based International Classification of Diseases version-10 (ICD-10) codes for COVID-19 (n=1943) between February 1, 2020 and December 31, 2020. Population controls (n=217 730) and propensity score—matched controls (n=38 860) were also drawn from the UK Biobank during the same period. Proportional hazard models were used to evaluate COVID-19 for association with long-term (>1000 days) risk of MACE and as a coronary artery disease risk equivalent. Additional analyses examined whether COVID-19 interacted with genetic determinants to affect the risk of MACE and its components.

 

Read more click here